MX9405371A - Derivado de naftilo. - Google Patents

Derivado de naftilo.

Info

Publication number
MX9405371A
MX9405371A MX9405371A MX9405371A MX9405371A MX 9405371 A MX9405371 A MX 9405371A MX 9405371 A MX9405371 A MX 9405371A MX 9405371 A MX9405371 A MX 9405371A MX 9405371 A MX9405371 A MX 9405371A
Authority
MX
Mexico
Prior art keywords
naftile
derivative
6mna
nabumetone
dementia
Prior art date
Application number
MX9405371A
Other languages
English (en)
Inventor
Michael Sidney George Clark
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9405371A publication Critical patent/MX9405371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona el uso de nabumetona o 6MNA en lafabricación de una medicamento para utilizarse en tratamiento y/oprevención de la demencia.
MX9405371A 1993-07-15 1994-07-14 Derivado de naftilo. MX9405371A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939314693A GB9314693D0 (en) 1993-07-15 1993-07-15 Naphthyl derivatives for treatment method

Publications (1)

Publication Number Publication Date
MX9405371A true MX9405371A (es) 1995-01-31

Family

ID=10738900

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9405371A MX9405371A (es) 1993-07-15 1994-07-14 Derivado de naftilo.

Country Status (10)

Country Link
US (1) US5695774A (es)
EP (1) EP0708641A1 (es)
JP (1) JPH09500121A (es)
AP (1) AP460A (es)
AU (1) AU7188194A (es)
GB (1) GB9314693D0 (es)
IL (1) IL110303A0 (es)
MX (1) MX9405371A (es)
WO (1) WO1995002399A1 (es)
ZA (1) ZA945083B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7485900A (en) * 1999-09-14 2001-04-17 Copley Pharmaceutical Inc. Delayed release nabumetone formulation
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
WO2004026246A2 (en) * 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2015155544A1 (en) * 2014-04-10 2015-10-15 Patrick Crowley Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA960689A (en) * 1967-01-13 1975-01-07 Syntex Corporation 2-naphthyl acetic acid derivatives and compositions
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
US4061779A (en) * 1973-09-11 1977-12-06 Beecham Group Limited Naphthalene derivatives having anti-inflammatory activity
GB9019413D0 (en) * 1990-09-05 1990-10-17 Beecham Group Plc Topical treatment and composition
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia

Also Published As

Publication number Publication date
EP0708641A1 (en) 1996-05-01
ZA945083B (en) 1995-05-26
AU7188194A (en) 1995-02-13
AP460A (en) 1996-02-16
US5695774A (en) 1997-12-09
JPH09500121A (ja) 1997-01-07
GB9314693D0 (en) 1993-08-25
IL110303A0 (en) 1994-10-21
WO1995002399A1 (en) 1995-01-26
AP9400656A0 (en) 1994-07-31

Similar Documents

Publication Publication Date Title
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
SV1997000079A (es) Dihidrato d de olancepina ref. x- 11062t
NO964966D0 (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
BR0211769A (pt) Combinações antineoplásicas
MX9305054A (es) Usos novedosos de il-4 y/o il-10, y anticuerpos contra los mismos.
BR9612203A (pt) Amidas tricíclicas úteis para a inibição da função da g-pro-teína e para o tratamento de doenças proliferativas
NO20056021L (no) Anvendelse av CS-866 til fremstilling av et medikament
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
MX9405371A (es) Derivado de naftilo.
SE9904377D0 (sv) Pharmaceutical combinations
TR28109A (tr) Duman halinde dezenfekte eden formülasyonlar.
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
ES2078904T3 (es) Nuevos derivados de neplanocina.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
ES2173911T3 (es) Uso de glicosidos en vitamina d para el tratamiento o prevencion de la osteoporosis.
MX9301935A (es) Compuestos para el tratamiento de alteraciones neurodegenerativas.
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
CL2004001291A1 (es) Composicion farmaceutica que comprende compuestos carbociclicos y heterociclicos; y su uso para el tratamiento o profilaxis de la infeccion por influenza.
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
ES2055421T3 (es) Uso de clormetiazol en la fabricacion de un medicamento para la prevencion y/o el tratamiento de neurodegeneracion.
PT804199E (pt) Uso de penciclovir para o tratamento de nevralgias pos-herpeticas
ES2175099T3 (es) Uso de forskolina o extractos que la contienen en la fabricacion de un medicamento para el tratamiento de la adiccion al alcohol.
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.
AR006437A1 (es) Uso de monohidrocloruro de n-(endo-9-metil-9-azabiciclo [3.3.1]non-3-il)-1- metilimidazol-3-carboxamida, para la fabricacion de un medicamento para eltratamiento o la profilaxis de diarrea y una composicion farmaceutica que lo contiene

Legal Events

Date Code Title Description
FA Abandonment or withdrawal